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Objective: Hyperhomocysteinaemia is associated with peripheral arterial disease (PAD). There are inter-individual
variations in the metabolism of homocysteine because of genetic polymorphisms. This study analyzed the role of one
polymorphism that is associated with raised homocysteine, as a risk factor for PAD.
Methods: This study considered the association of methylenetetrahydrofolate reductase (MTHFR) C677T polymorphisms
with the incidence of PAD by performing a case-control study and a cross sectional study of homocysteine levels. We
recruited 133 patients with PAD in Norfolk and compared theMTHFR allele distribution with 457 healthy individuals.
We also carried out a meta-analysis to place our data within the context of other published studies. We searched Medline,
Embase, and Cochrane databases up to March 2008 for any studies on the association between MTHFR C677T
polymorphism and PAD.
Results: The MTHFR C677T allele frequencies in the cases and controls were 0.37 and 0.33, and the odds ratios for the
association of the 677 T allele or TT genotype with PAD were 1.18 (95% Confidence Interval [CI] 0.89, 1.58) and 1.99
(95% CI 1.09, 3.63). Homozygotes for the MTHFR C677T mutation had higher concentrations of plasma total
homocysteine, odds ratio 2.82 (95% CI 1.03, 7.77) compared to homozygotes for the MTHFR 677 CC genotype.
Twelve of 72 articles retrieved from the database search reported the prevalence of mutations in PAD patients. A
meta-analysis of 9 appropriate studies, including our own, showed that being homozygous for the C677T allele was
associated with an increased risk of PAD, pooled odds ratio 1.36 (95% CI 1.09, 1.68).
Conclusion:We have found a strong association between raised homocysteine, the TT genotype, and PAD. (J Vasc Surg
2009;49:711-8.)Vascular diseases, including peripheral arterial disease
(PAD), are responsible for about 65% of cases (approxi-
mately 3,200) of all lower limb amputations in the UK
every year.1 The treatment of PAD accounts for more than
35,000 hospital admissions and over 220,000 hospital bed-
days in England annually.2 One of the mainstays of PAD
treatment is risk factor management. This comprises the
modification of traditional risk factors such as hypertension,
hypercholesterolaemia, diabetes, smoking, and platelet ag-
gregation.3 Although these treatments are effective, the
control of atherosclerosis is not easily and completely
achievable. For example, the use of infrainguinal bypass
graft surgery and medical therapy for treatment of PAD
have up to a 40% failure rate.4,5 This has led to the search
for other PAD risk factors that may be amenable to preven-
tive therapy.
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Vascular Surgery.doi:10.1016/j.jvs.2008.10.004Elevated plasma homocysteine (Hcy) is one of the
suggested risk factors for endothelial dysfunction.6 There is
evidence of an association between raised plasma Hcy and
an increased risk of developing peripheral arterial dis-
ease.6-8 A causal relationship, however, has not been estab-
lished.
The metabolism of Hcy depends on many factors in-
cluding the availability of cofactors such as folate and
vitamin B12 and the genes encoding enzymes that have a
role in Hcy metabolism. Premature PAD has a strong
familial association9,10 suggesting an underlying genetic
basis, although other environmental factors such as familial
smoking behavior may also be involved. Polymorphic vari-
ants of one of the enzymes involved in Hcy metabolism,
MTHFR, and Hcy concentration have been studied in
large meta-analyses of patients suffering from ischaemic
heart disease11 and stroke,12 with the authors concluding
that there is a causal relationship between Hcy concentra-
tion and cardiovascular disease. There is no previous meta-
analysis of the effect of the MTHFR gene andHcy levels on
the risk of developing PAD.
MTHFR is an enzyme that catalyses the conversion of
5,10-methylenetetrahydrofolate to 5-methyltetrahydrofo-
late, with nicotinamide adenine dinucleotide phosphate
(NADPH) and the vitamin riboflavin as cofactors. MTHFR
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morphisms.13-15 Kang et al first described an association of
MTHFR C677T with cardiovascular disease (CVD) in
1988.16 This mutation results in a valine to alanine substi-
tution at amino acid 677 of the protein; the homozygous
and heterozygous genotypes (CT) and (TT) are associa-
ted with raised homocysteine concentrations and lower
MTHFR enzyme concentrations.17 It is possible that car-
riers of MTHFR polymorphisms may be at a higher risk of
PAD but a number of previous small studies have drawn
conflicting conclusions. It has been shown that the children
of families with severe atherosclerosis have higher plasma
levels of Hcy particularly after the age of 12 years.18 If
certain genotypes are risk factors for atherosclerosis, indi-
viduals at risk of premature PAD may be identified at a
subclinical stage that merits early intervention.
METHODS
Norwich case-control study
MTHFR 677 polymorphisms were examined in a pop-
ulation with PAD and in a healthy control population.
Participants
One-hundred thirty-three patient volunteers were re-
cruited from referrals to the vascular out-patient clinics at
the Norfolk and Norwich and James Paget University
Hospitals. These teaching hospitals serve a population of
more than 800,000 in the east of England. The volunteers
were recruited for a double blind randomized controlled
trial (known as FOLCLAUD) assessing the outcomes of
folic acid supplementation on the clinical signs of PAD, and
approximately 20% of those who were eligible for the study
volunteered to participate. PAD was defined as arterial
insufficiency or intermittent claudication together with an
ankle brachial pressure index (ABPI) 0.9 in either of the
lower limbs. Patients were considered for participation in
the study if a number of criteria were met; all subjects had a
clinical history of PAD with appropriate medical manage-
ment, a bodymass index that was between 18.5 and 40, and
their ages ranged from 45 to 85 years.
Patients with very advanced disease (eg, those with
gangrene, rest pain or tissue loss) or those with chronic
renal failure (renal failure was defined as serum creatinine
130 mmol/L) and diabetes mellitus were excluded, as
were patients receiving anti-folate or B vitamin medication
or those with autoimmune vasculitis.
DNA was analyzed for 130 of the 133 FOLCLAUD
recruits; an EDTA blood sample was not available for 3 of
the patients who were withdrawn from the study for angio-
plasty.
Controls were 457 apparently healthy male volunteers
recruited through a local community media-advertising
campaign for a genetic and iron homeostasis study.19 The
mean age of the volunteers was 60 years (range, 40-80
years). The samples were stored at 80 °C at the Human
Nutrition Unit of the Institute of Food Research. These
samples were anonymized for the subsequent genetic stud-ies and no investigations were performed to preclude PAD
at the time of recruitment.
The study was approved by the East Norfolk and
Waveney Research Governance Committee and by the
Norfolk Research Ethics Committee.
MTHFR genotyping
Genomic DNA was isolated from potassium EDTA
anti-coagulated whole blood (stored at 20 °C until use)
using Generation columns (Gentra, Minneapolis, Minn).
Genotyping was performed by polymerase chain reaction
(PCR) using the sense and antisense primers 5=-GGGTC-
AGAAGCATATCAGTCATG-3= and 5=CACAAAGCG-
GAAGAATGTGTC-3=. One-hundred ng DNA, 10 l of
primer and 10l of 2X PCR Thermo Start Mastermix
(ABgene UK, Epsom, England) were used for each PCR
reaction, which was comprised of 38 cycles with an anneal-
ing temperature of 55°C. The PCR products were then
digested withHinf I restriction enzyme and analyzed by gel
electrophoresis on a 3% Metaphor agarose gel (FMC Bio-
products, Lichfield, UK). PCR was carried out in a diag-
nostic laboratory with separate rooms dedicated to set-up
and analysis and subject to national quality assurance test-
ing. Each assay batch included controls for the 3 possible
genotypes, in triplicate, and 5 no DNA template controls.
Ten percent of samples were re-screened (ie, genotyped in
duplicate in different batches and checked for concor-
dance).
Homocysteine levels
Homocysteine levels were analyzed for the PAD cohort
only. All patients were asked to fast overnight and refrain
from smoking and alcohol for 24 hours prior to the test.
Plasma was collected from potassium EDTA anti-
coagulated whole blood that was centrifuged for 15 min-
utes at 4°C to avoid temperature dependent release of Hcy
from blood cells.
Hcy was measured by using a fluorescence polarization
immunoassay analyzed by the IMx analyzer (Abbott Diag-
nostics, Abbott Park, Ill) according to the manufacturer’s
protocol.
Methods of the systematic review and meta-analysis
Search strategy. Medline, Embase, and Cochrane da-
tabases were searched for the period of January 1950 to
March 2008. using the terms “peripheral arterial disease” or
“peripheral vascular disease” or “intermittent claudication”
merged with “5,10-methylenetetrahydrofolate reductase,”
“methylenetetrahydrofolate reductase” (or MTHFR) or
“MTHFR_HUMAN”. The bibliographies of the relevant
papers were manually checked.
Eligibility criteria. Case-control, prospective studies,
and clinical trials on the association of MTHFR genotypes
and PAD were considered for the meta-analysis.
Fig 1 shows a flow diagram for the study selection
process. The studies were included if the prevalence of
MTHFR 677 alleles were compared in PAD patients and a
suitable control cohort (case control studies and nested
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be healthy individuals, coming from the same population
and ethnic origin.
We accepted studies where PAD was defined, based on
an ABPI of less than 0.9 or clinical signs and symptoms of
intermittent claudication, or the presence of rest pain or
tissue gangrene (Fontaine stage III or IV) or clearly dimin-
ished foot pulses plus obstruction of one major peripheral
artery on angiography or duplex scan. Lower limb ampu-
tation due to vascular causes, revascularisation by bypass
grafts, or angioplasty were also considered as PAD.
Studies were excluded if there was evidence of popula-
tion stratification or if it was not possible to check the allele
frequency data from the control cohort using the Hardy-
Weinberg equilibrium.
Study selection for the meta-analysis was carried out by
4 of the authors (N.K., F.M., Y.L., B.J.). Data for analysis
were extracted independently by 2 of the authors (B.J.,
N.K.), and the data sets cross-checked. Any discrepancies
were resolved through discussion and consensus.
Data were also extracted from studies that had re-
ported mean plasma Hcy levels for each genotype to
analyze any association of hyperhomocysteinaemia and
MTHFR mutations.
Statistical analysis
Genotype data was collated on Microsoft Excel (Mi-
crosoft Corp, Redmond, Wash). For our study, and each of
those included in the meta-analysis, allele frequencies were
determined by the gene counting method and the control
populations were tested for deviation from
Hardy-Weinberg equilibrium (HWE) using a two tailed
chi-square test. A P value less than 0.05 was considered
significant for deviations.
For our study, and each of those included in the meta-
Fig 1. A flow diagram of the study selection process.analysis, the odds ratios were determined for (1) carryingthe C677T allele and (2) being homozygous for the
C677T allele compared with being homozygous for the
wild type (677C) genotype in PAD cases and controls. For
the meta-analysis, the pooled odds ratios (fixed-effects
model, inverse variance method) for the association of the
C677T allele or the C677T homozygous genotype with
PAD and the test for heterogeneity were calculated using
Stats Direct (Stats Direct Ltd, Cheshire, UK). Heteroge-
neity was assessed using the I2 statistic, with I2 values of
40% being considered unimportant.20
All of the studies, except for the study by Rassoul et al,
indicated the use of investigations such as the ABPI, ultra-
sound, or arteriography to define their cases of PAD.
Exclusion of Rassoul’s study from the meta-analysis did not
change the magnitude or direction of the association, with
OR 1.40 (95% CI 1.12, 1.74, P .003) for homozygosity
of the MTHFR C677T allele, and OR 1.09 (95% CI 0.00,
1.21, P  .09) for T allele frequency.
RESULTS
Baseline characteristics and atherosclerotic risk factors
in the 133 PAD patients are summarized in Table I. The
mean age of patients was 70 years (range, 48-86 years). The
mean age of the control group, which comprised 457
Table I. Baseline characteristics of peripheral arterial
disease patients
Characteristics Total
Total no. 133
Male, n (%) 90 (68%)
Age (years)* 69.68  8.22*
BMI (kg/m2)* 27.22  3.90*
Smoker n (%) 48 (36%)
Hypertension n (%) 87 (65%)
Systolic BP (mmHg)* 146.41  19.92*
Diastolic BP (mmHg) 80  14
Pulse rate 68  12
tHcy* 14.1  5.7*
Plasma folate 14.00  15.00
RBC folate 658.25  460.05
TC (mmol/L) 4.40  1.20
LDL (mmol/L) 2.50  1.00
HDL (mmol/L) 1.18  0.41
History of CAD, n (%) 46 (34.6%)
History of stroke, n (%) 5 (3.76%)
The mean values ( standard deviations) are indicated with * and the
remaining values are median values.
BP, Blood pressure; BMI, body mass index; CAD, coronary artery disease;
HDL, high-density lipoprotein; LDL, low density lipoprotein; RBC, red
blood cell; TC, total cholesterol.
Table II. Genotype distribution of participants
Genotypes PAD Cases Controls
MTHFR 677 CC 43.8% (57/130) 42.9% (196/457)
MTHFR 677 CT 39.2% (51/130) 48.8% (223/457)
MTHFR 677 TT 16.9% (22/130) 8.3% (38/457)
PAD, Peripheral artery disease.individuals, was 60 years (range, 40-80 years).
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The C677T allele frequencies in the cases and controls
were 0.37 and 0.33 respectively, and the genotype distri-
bution is shown in Table II. The odds ratios for the
association of the C677T allele or C677T homozygous
genotype with PAD were 1.18 (95% CI 0.89, 1.58) and
1.99 (95% CI 1.09, 3.63) respectively.
HWE analysis
The control group was significantly out of Hardy-
Weinberg equilibrium, with TT homozygotes under-
represented.
Homocysteine levels
The mean Hcy level for the PAD patients was 14.09
mol/L (range, 6.29 to 43.3 mol/L). There was a
marked increase in Hcy levels associated with the presence
of the C677T MTHFR allele. The odds ratio for the
association of the C677T allele or C677T homozygous
genotype with anHcy level that was above the mean for the
cohort was 2.09 (95% CI 0.95, 4.60) and 2.82 (95% CI
Table III. The studies included in the meta-analysis: stud
Hardy-Weinberg analysis of the genotypes from the contro
Lead Author/ Year
of study Country
Diagnostic criteria for cases
of PAD
Verhoef 1998 Netherlands Clinical criteria confirmed by
angiography and
ultrasound.
Rassoul 2000 Germany All patients were Fontaine
stage III and IV
Fowkes 2000 UK ABPI was used in baseline
studies and World Health
Organization intermittent
claudication questionnaire
was used on follow-up
Ciccarone 2003 Italy Clinical criteria confirmed by
ultrasound.
Jones 2005 New Zealand Clinical criteria were
confirmed by ABPI and
arteriography.
Mueller 2005 Austria Clinical criteria were
confirmed by ABPI and
angiography
Pollex 2005 Canada ABPI was used and World
Health Organization
intermittent claudication
questionnaire
Sofi 2005 Italy All patients were Fontaine
stage II to IV and
confirmed by ABPI
FOLCLAUD 2008 England Patients with intermittent
claudication and arterial
insufficiency were
confirmed by ABPI
ABPI, Ankle brachial pressure index; HWE, Hardy-Weinberg equilibrium;1.03, 7.77) respectively.Meta-analysis results
The characteristics of the study designs and participants
included in the meta-analyses are presented in Table III.
Twelve studies had reported the prevalence of MTHFR
genotypes in patients with PAD. Two studies were ex-
cluded because they did not have a suitable PAD free
control.21,22 The control cohort for one of these studies
were newborn babies in what may be an ethnically diverse
population.21 One study had not reported genotypes of
participants with PAD separate from other diseases.23 An-
other study had not reported the distribution of homozy-
gotes and heterozygotes.24
Table IV and Fig 2 show the results from 1432 cases
with PAD compared with 2405 healthy individuals from
the nine studies, including FOLCLAUD.25-32 From this
meta-analysis, there was no evidence to suggest that the
C677T MTHFR allele frequency was increased in patients
with PAD; pooled odds ratio 1.08 (95% CI 0.98, 1.19).
There was a moderate degree of heterogeneity in this
meta-analysis, with an I2 value of 45%. Fig 2, A clearly
illustrates the highly varied nature of the odds ratio among
ign, baseline characteristics of the patients, and
orts
ber of PAD cases with
otype data (% who were
males) Age of PAD group
P value for deviations
from HWE for
control cohorts
48 (Not shown) Not shown .03
85 (100) 60  11 ns
80 (51) 65.9 .02
130 (Not shown) Not shown .04
226 (57.8) 71.6  9.1 ns
433 (62.8) 68 ns
20 (35) 48.0  11.2 ns
280 (77.1) 69 (range, 35-90) ns
130 (67.8) 69.7  8 .02
n-significant (P  .05); PAD, peripheral artery disease.y des
l coh
Num
gen
ns, nothe included studies.
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allele (TT genotype) were at greater risk of developing
PAD compared with individuals who were homozygous for
the 677C MTHFR allele (CC genotype), odds ratio 1.36
(95% CI 1.10, 1.68). There was little heterogeneity (I2 
7.6%) in this analysis, with 6 of the 8 studies showing a
consistent association. Random effects meta-analysis
yielded pooled estimates that were similar in direction and
magnitude to the fixed effects model, pooled OR 1.07
Fig. 2. (A)Meta-analysis of MTHFR C677T allele frequ
carrying the MTHFR C677T allele compared with those
ratio  1.08 (95% CI 0.98, 1.19); Z (test odds ratio d
(B) Meta-analysis of MTHFR C677T homozygous geno
individuals who were homozygous for the MTHFR C67
wild type allele (CC vs TT). Pooled odds ratio  1.36 (9
P  .0052; I2 (inconsistency)  7.6%.(95% CI 0.93, 1.23; P  .36) for the presence of the Tallele, and pooled OR 1.35 (95% CI 1.08, 1.69, P .009)
for the MTHFR homozygous genotype frequency (CC
versus TT) comparison.
HWE analysis
For 7 of the 9 studies, including FOLCLAUD, and
comprising 80% of the subjects, TT homozygotes were
under-represented in the control cohorts.27-32 Deviations
from HWE were significant (P  .05) in 4 studies (see
in patients with PAD.Odds ratios for PAD in individuals
were homozygous for the wile type allele. Pooled odds
from 1)  1.51, P  .13; I2 (inconsistency)  45%.
requency in patients with PAD. Odds rations for PAD in
lele compared with those who were homozygous for the
I 1.10, 1.68); Z (test odds ratio differs from 1)  2.79,ency
who
iffers
type f
7T al
5% CTable III).
al arte
us for
JOURNAL OF VASCULAR SURGERY
March 2009716 Khandanpour et alMTHFR and concentrations of plasma Hcy in
patients with PAD
Only 1 of the 8 studies included in the meta-analysis, in
addition to our own, reported the mean plasma Hcy levels
for each MTHFR genotype (see Table V). In both studies,
the MTHFR C677T mutation is associated with increased
plasma Hcy concentrations.
DISCUSSION
Previous meta-analyses suggesting a causal relationship
between raised Hcy and CVD11,12 used a Mendelian ran-
domization approach by considering both the association
between the MTHFR genotype and CVD and the associa-
tion between the phenotype (raised Hcy) and CVD. This is
the first meta-analysis that considers the association be-
tween the MTHFR genotype and PAD and it includes data
from our own primary study that explores the associations
between genotype (MTHFR C677T), phenotype (raised
Hcy), and PAD.
In our case-control study, PAD patients recruited
Table IV. MTHFR C677T distribution
Lead Author /Year
of study
Odds of T allele
prevalence in PAD
Odds o
prevalenc
Verhoef 1998 30/66 181
Rassoul 2000 27/75 53
Fowkes 2000 40/120 189
Ciccarone 2003 117/143 185
Jones 2005 150/302 174
Mueller 2005 264/602 267
Pollex 2005 8/32 22
Sofi 2005 259/301 213
FOLCLAUD 2008 95/165 299
Lead Author/Year
of study
Prevalence with
CC genotype;
cases (controls)
Prevalen
TT ge
(cont
Verhoef 1998 26 (129) 8 (
Rassoul 2000 43 (29) 11 (
Fowkes2000 46 (132) 6 (
Ciccarone 2003 41 (60) 28 (
Jones 2005 106 (134) 76 (
Mueller 2005 207 (204) 30 (
Pollex 2005 12 (96) 0 (
Sofi 2005 83 (106) 62 (
FOLCLAUD 2008 57 (196) 22 (
CC, homozygous for the MTHFR 677C allele or wild type; PAD, Peripher
Table V. Mean plasma Hcy levels in peripheral artery dise
study
Author
Hcy concentration (mol/L)
and standard deviation for
individuals with CC genotype
Hcy concentrati
and standard d
individuals with
FOLCLAUD 12.5  2.59 14.5 
Rassoul 15.3  7.54 18.1 
CC, homozygous for the MTHFR 677C allele or wild type; TT, homozygothrough FOLCLAUD were found to have high Hcy levelsand the prevalence of the MTHFR C677T heterozygous
(CT) and homozygous (TT) genotypes was higher than in
a cohort of healthy volunteers recruited from the same local
population. The odds ratio for the risk of PAD in those with
the TT genotype and the concomitant rise in mean Hcy
levels in these individuals suggests a strong association that
merits further investigation. Our control cohort was not
selected for absence of disease and that, coupled with an
average age of 60, means that a proportion of the control
cohort could potentially develop PAD later on. The use of
ABPI in males of this age group indicate that between 4% and
16%mayhave evidence of PAD.33While this could have led to
us underestimating the associations of genotype and PAD, we
have attempted to compensate for this type II error by pooling
our data with other studies in a meta-analysis.
The meta-analysis combines our data with that of eight
other studies. In our analysis of the genotypes of 1432
patients with PAD and 2405 controls, we found that the
MTHFR C677T allele increased the risk of PAD in ho-
mozygotes (TT genotype) with an odds ratio of 1.99 (95%
llele
ontrols
Odds ratio for presence of
T allele in PAD cohort
95% Confidence
Interval
0.91 (0.57, 1.45)
0.79 (0.46, 1.37)
0.73 (0.49, 1.07)
1.06 (0.77, 1.22)
1.11 (0.85, 1.45)
0.98 (0.80, 1.21)
2.43 (0.99, 5.92)
1.40 (1.10, 1.78)
1.18 (0.89, 1.58)
th Odds ratio for prevalence
of MTHFR CC to TT
genotype in PAD cohort
95% Confidence
Interval
1.04 [0.44, 2.50]
0.74 [0.28, 1.97]
0.82 [0.312, 2.16]
1.24 [0.65, 2.35]
1.26 [0.84, 1.9]
1.14 [0.64, 1.99]
Not applicable Not applicable
2.03 [1.24, 3.32]
1.99 [1.09, 3.63]
ry disease; TT, homozygous for C677T.
atients from this study and data extracted from previous
mol/L)
ion for
enotype
Hcy concentration (mol/L)
and standard deviation for
individuals with TT genotype
Difference between
Mean value for TT
and CC genotypes
17.1  6.5 4.6 mol/L increase
22.6  7.4 7.3 mol/L increase
C677T allele.f T a
e in c
/363
/117
/411
/239
/390
/599
/214
/347
/615
ce wi
notype
rols)
38)
10)
21)
33)
76)
26)
0)
39)
38)ase p
on (
eviat
CT g
3.6
10.2CI 1.09, 3.63). There was also a non-significant over-
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PAD group (see Fig 2, A).
The data in Table V show that in our study there was a
36% difference in mean Hcy levels between the wildtype
and TT genotypes and a 47% difference in the study by
Rassoul et al. The PAD patients from these studies had very
similar mean ages and gender distributions and Hcy levels
were measured using blood samples taken after overnight
fasting. The rises in Hcy associated with the TT genotype
are nearly twice as high as those derived from a meta-
analysis of CVD patients, most of whom had coronary
artery disease; it was shown that those with the TT geno-
type had a 25% higher mean Hcy levels.34 A meta-analysis
of 25 studies demonstrated that patients with PAD have a
stronger association with raised HcY than patients with
coronary artery disease or cerebrovascular disease.35
There were several possible limitations to our meta-
analysis but publication bias seems unlikely given that most
of the studies included were not statistically significant and
were considered to have negative findings.
The first potential problem is the heterogeneity in
study design and subject selection. Some of the studies had
a case-control design, others were nested case-controls in
studies of type 2 diabetes; whereas diabetic patients were
excluded from FOLCLAUD. Nevertheless, there was only
a small amount of statistical heterogeneity (I2 7.6%) seen
in the meta-analysis of MTHFR C677T homozygous ge-
notype frequency, indicating that there is indeed a consis-
tent association with PAD.
The paucity of data is an important limitation as each of
the primary studies described relatively small patient co-
horts (from 20 to 433 PAD subjects) and only 1432
patients were included in the meta-analysis. Our finding of
the increased risk of PAD associated with the TT genotype
needs to be replicated in a wider range of settings and with
larger sample sizes. In view of the moderate heterogeneity,
we cannot confidently rule out a weak association between
the CT heterozygous genotype and PAD as the confidence
intervals were between 0.98 and 1.19, with a point estimate
of 1.08. The wide confidence intervals of the existing
studies indicate that these studies may have lacked power to
detect the association (type II error). The sample sizes need
to be much larger, with standardized conduct and report-
ing as recommended by Little et al.36
The third possible limitation of the meta-analysis re-
lates to the data from the control cohorts. When we anal-
ysed the genotype frequencies for adherence to HWE, we
found that in 7 of the 9 studies included in the meta-
analysis, comprising 80% of the subjects, TT homozygotes
were under-represented in the control cohorts. It has been
shown that adherence to, or violations from, HWE in
disease-free controls can affect the results in gene-disease
association studies.37 Deviations from HWE can indicate
genotyping errors or population stratification which might
mean that postulated associations warrant further evidence.
It should be noted that 8 of the 9 studies (including
FOLCLAUD) in the meta-analysis used the same genotyp-
ing method, Hinf I digestion of a PCR product, so it isimportant to confirm that HWE deviations are not due to
misinterpretation of incomplete restriction enzyme diges-
tion of PCR products. However, in the FOLCLAUD study
we were able to rule out genotyping errors because of
rigorous quality assurance steps in our method.
Deviations from HWE could also indicate altered fit-
ness for a particular genotype. This could apply to the
homozygous genotype of MTHFR C677T, which is
known to affect numerous and diverse disease pheno-
types.38 This under-representation of TT homozygotes has
also been observed in other studies of the MTHFR C677T
polymorphism.39 It is possible that this may reflect a pro-
cess of differential survival. Whatever the cause, the phe-
nomenon is likely to apply to both the test and control
parent populations so is a necessary feature of matched
controls for studies of this polymorphism.
Our primary study derives from a double blind ran-
domized control trial assessing the outcomes of folic acid
supplementation on clinical signs and biomarkers including
gene expression, and may improve our understanding of
the role of genetics in the pathophysiology of PAD.
Tony Lynn (Human Nutrition Unit, University
of Sheffield) performed the Hcy analyses for this study.
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